AVIDITY BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.86 USD | -0.74% |
|
-2.22% | +196.80% |
Presenter SpeechGeoffrey Meacham (Analysts)Second day of the BofA Healthcare Conference. My na...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Sector
Pharmaceuticals
Calendar
2024-06-12
- Investor and Analyst Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
26.86
USD
Average target price
45.25
USD
Spread / Average Target
+68.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +196.80% | 2.59B | |
| -2.29% | 89.38B | |
| -3.95% | 37.92B | |
| -13.07% | 32.04B | |
| +63.05% | 26.03B | |
| -22.14% | 14.14B | |
| -7.96% | 12.88B | |
| -9.33% | 11.77B | |
| -46.33% | 10.85B | |
| +5.77% | 8.92B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Transcript : Avidity Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08
